--- title: Cardiac Webinar Replay description: Explore a free webinar on investigational stem cell therapy for cardiovascular issues, featuring 2 expert Doctors for when standard treatments fail. --- ![Hemostemix Logos (400 x 100 px)](https://hemostemix.com/hubfs/Hemostemix%20Logos%20(400%20x%20100%20px).png) [Free Webinar Replay - Recorded May 5, 2026](https://hemostemix.com/cardiac-webinar-replay#form) # When Standard Of Care Heart Treatment Isn't Enough Prof. Dr. Ernst von Schwarz and Dr. York N. Hsiang on investigational stem cell therapy for cardiovascular ischemia, angina, and ischemic cardiomyopathy. One hour. Now available to watch. [Watch the Replay](https://hemostemix.com/cardiac-webinar-replay#form) **Prof. Dr. von Schwarz** 150+ Peer-Reviewed Publications  Cedars Sinai and UCLA  **Dr. York N. Hsiang** Phase I/II VesCell (ACP-01) Principal Investigator · Professor Emeritus, UBC **Published Phase I Angina Data** 50% CCS Angina Class Reduction at 3 Months *Disclosure: Prof. Dr. von Schwarz and Dr. Hsiang have a commercial relationship with Hemostemix Inc. * WHAT THIS CONVERSATION COVERS ## A new area of investigation. One that starts with your own blood. For patients living with angina, cardiovascular ischemia, or cardiomyopathy, the limits of standard treatment are not a knowledge gap. They are a daily reality. The question physicians like Prof. Dr. von Schwarz and Dr. Hsiang have spent decades asking is what comes next when those limits are reached. VesCell is an investigational autologous cell therapy derived from the patient's own blood. In this 60-minute conversation, two of its lead researchers discuss what the published data shows and what that means for patients still searching for answers. - How autologous stem cell therapy works at the biological level, specifically the formation of new blood vessels in ischemic tissue - What published Phase I data shows for angina, and what published outcomes data shows for cardiomyopathy  - How Prof. Dr. von Schwarz has applied investigational stem cell therapy in cardiac practice over 30 years and what he has observed  - The clinical question at the center of this research: at what point does cell therapy become the right conversation to have  - What the eligibility and evaluation process for VesCell (ACP-01) research looks like ## Watch the full replay. It is free. Enter your information below and we will send your replay link immediately. VesCell is an investigational therapy. This webinar is for informational purposes only and does not constitute medical advice or a clinical consultation. THE PHYSICIANS BEHIND THE RESEARCH ## These two physicians have spent their careers asking what is possible when standard of care stops working. ![EV](https://hemostemix.com/hubfs/EV.webp) ###### Prof. Dr. Ernst von Schwarz MD, PhD, FESC, FACC, FSCAI Triple Board-Certified Cardiologist Professor of Medicine, Cedars Sinai and UCLA Medical Director, Heart Stem Inc.  Prof. Dr. von Schwarz began investigating cell therapy for cardiac patients in 1996. Thirty years later he has published over 150 peer-reviewed papers and built his clinical practice around one question: what do we do for the patients conventional cardiology cannot reach. ![YH](https://hemostemix.com/hubfs/YH.webp) ###### Dr. York N. Hsiang M.B. Ch.B., MHSc., FRCSC · Professor Emeritus of Surgery, UBC Former Head of Vascular Surgery, VGH - Principal Investigator, Phase I/II VesCell (ACP-01) Trial Dr. Hsiang led the clinical investigation of VesCell (ACP-01). He oversaw the data, reviewed the outcomes, and published the results. When he speaks to the science, it is because he built it. WHAT THE PUBLISHED DATA SHOWS ## Published. Peer-reviewed. Investigational. PHASE I ANGINA DATA --- 50% Reduction in CCS angina class at 3 months Chaithiraphan N=106 · Schubart N=54   References: Chaithiraphan S, et al. Transcoronary injection of angiogenic cells precursors in autologous stem cell in ischemic cardiomyopathy: a clinical study of 106 cases in Thailand. Asean Heart Journal. 2009;17:13–22. [Read the Study](https://hemostemix.com/hubfs/ASEAN-Hearth-Journal.pdf?hsLang=en) Schubart JR, et al. Safety and outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy. Stem Cell Research and Therapy. 2023;14:308. doi:10.1186/s13287-023-03539-6. [Read the Study ](https://link.springer.com/article/10.1186/s13287-023-03539-6)   VesCell Clinical Safety Brief:  [Read the Brief](https://hemostemix.com/hubfs/VesCell-Safety-Brief.pdf?hsLang=en) CARDIOMYOPATHY OUTCOMES (SCHUBART ET AL., 2023) --- +7.2% LVEF improvement at 12 months · Ischemic cardiomyopathy (n=41, p\<0.004)   +12.2% LVEF improvement at 12 months · Non-ischemic dilated cardiomyopathy (n=8, p\<0.003)   66% Patients reported quality of life improvement at 6 months (33/50, retrospective patient-reported; no standardized instrument administered)  --- VesCell is an investigational therapy. These results are from specific published studies and do not constitute a guarantee of outcomes for individual patients. Safety and effectiveness continue to be studied.   WHO THIS REPLAY IS FOR ## This recording is for you if: - You or someone you care for has been diagnosed with angina, cardiovascular ischemia, or cardiomyopathy and standard treatment has not provided sufficient relief  - You want to understand what the current investigational research shows, explained by the physicians who conducted it  - You have questions about whether VesCell research may be relevant to your situation  - You are ready to have a different kind of conversation about what is possible  [Send Me the Replay](https://hemostemix.com/cardiac-webinar-replay#form) Is a clinical consultation right for you? Hemostemix is pursuing LARTA authorization for VesCell therapy at Doctors Hospital, The Bahamas. A protocol-based study is under development. Understand if you or someone you care for is eligible.   Schedule a Consultation VesCell (ACP-01) is an investigational autologous angiogenic cell therapy. It is not approved by the FDA or any other regulatory authority. This webinar is for informational purposes only and does not constitute medical advice, a treatment recommendation, or a clinical consultation. Individual patient outcomes may vary. Speak with your physician about your specific medical situation.   Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0)